| 
 | Webcast
ImmunoGen, Inc. at Biotechnology Industry Organization CEO & Investor Conference (Live)
02/09/10 at 2:30 p.m. ET |
| | |
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen’s cancer-cell killing agents specifically to tumor targets. In addition to the Company’s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s collaborations with Genentech (a wholly owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.... More >>Shareholder Inquiries
Inquiries related to the Company may be directed to the Investor Relations department at our headquarters. Communications related to stock and transfer requirements, including lost stock certificates and change of name or address, should be directed to the Transfer Agent.
| Corporate
Headquarters
ImmunoGen, Inc.
830 Winter Street
Waltham, MA 02451-1477
Phone: (781) 895-0600
Email: info@immunogen.com
|
Transfer Agent and Registrar
Mellon Investor Services, LLC
Ridgefield Park, NJ
Phone: (800) 288-9541
www.melloninvestor.com/isd |  | Corporate
Counsel
Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
Boston, MA | Independent Accountants
Ernst & Young LLP
Boston, MA |
|
Receive E-mail Alerts | | Sign up to receive e-mail alerts whenever ImmunoGen posts new information to the site. Just enter your e-mail address and click Submit. |
|
